(Journal Article): Cholesterol Emboli Syndrome in Type 2 Diabetes: The Disease History of a Case Evaluated with Renal Scintigraphy
 
Piccoli GB, Sargiotto A, Burdese M, Colla L, Bilucaglia D, Magnano A, Consiglio V, Piccoli G, Picciotto G (Chair of Nephrology, Department of Internal Medicine, University of Turin, Corso Bramante 86-88, 10126 Torino, Italy., giorgina.piccoli(at)unito.it )
 
IN: Rev Diabetic Stud 2005; 2(2):92-96
Impact Factor(s) of Rev Diabetic Stud: 0.125 (2006)

Fulltext:    HTML  PDF

ABSTRACT: BACKGROUND: Cholesterol crystal emboli syndrome (CCE) is an emerging disease, whose progression reflects the currently observed increase in cardiovascular diseases. Diagnostic criteria shifted from pathological to clinical criteria: creatinine increase, skin lesions, recent endovascular interventions and severe vasculopathy). Diabetes, hypertension and diffuse vascular disease are inter-linked, major risk factors. The role of imaging techniques in the diagnosis and treatment of the disease has been little investigated thus far. The AIM of this report is to describe a case exemplifying the potentials for renal scintigraphy in CCE, an emerging disease in type 2 diabetic patients. THE CASE: a 75 year-old, type 2 diabetic for over 15 years, obese, hypertensive white man was referred to the Nephrology Unit after an acute coronary syndrome. Stenosis of the left renal artery was diagnosed from the angiography. Serum creatinine (baseline: 1.9 mg/dl) increased after multiple angioplasties to 3.3 mg/dl, then slowly returned towards baseline (2.2 mg/dl), but rose, on referral, to 3.9 mg/dl, with an increase in acute phase reactants and peripheral livedo reticularis, a picture highly suggestive of CCE. The first renal scintiscan showed a reduction of the parenchymal phase, and a non-homogeneous parenchymal pattern in the right dominant kidney. The patient was started on corticosteroid therapy with a prompt decrease in creatinine; four days later (creatinine 2.5 mg/dl) a second scintiscan showed an improvement of the peak time and of the radionuclide parenchymal transit, and was further confirmed two months later (creatinine 2.2 mg/dl). No modification was detected in the left kidney, presumably mechanically "protected" from the cholesterol shedding by the stenosis. CONCLUSIONS: This is the first description of an imaging demonstration of the morpho-functional substratum to the rapid clinical response of corticosteroid therapy in a case of CCE and type 2 diabetes, underlining the potential of 99mTc-MAG3 dynamic scintiscan in this disease.

TYPE OF PUBLICATION: Case Report

REFERENCES:

1. Darsee JR. Cholesterol embolism: the great masquerader. Southern Med J 1979. 72:174-180.
2. Moldveen-Geronimus J, Merriem JC. Cholesterol embolisa-tion: from pathologic curiosity to clinical entity. Circulation 1967. 35:1360-1366.
3. Kassirer JP. Atheroembolic renal disease. New Engl J Med 1969. 280:812-818.
4. Mayo RR Swartz RD. Redefining the incidence of clinically detectable atheroembolism. Am J Med 1996. 100:524-529.
5. Belenfant X, Meryer A, Jacquot C. Supportive treatment improves survival in multivisceral cholesterol crystal embolism. Am J K Dis 1999. 33:840-850.
6. Fukumoto Y, Tsutsui H, Tsuchihashi M, Masumoto A, Takeshita A. For the Cholesterol Embolism Study (CHEST) investigators. J Am Coll Cardiol 2003. 42:211-216.
7. Fine MJ, Kapoor W, Falanga V. Cholesterol crystal emboli-zation: A review of 221 cases in the English literature. An-guology 1987. 38:769-784.
8. Scolari F, Ravani P, Pola A, Guerini S, Cubani R, Movilli E, Savoldi S, Malcerti F, Maiorca R. Predictors of renal and patient outcomes in atheroembolic renal disease: a prospective study. J Am Soc Nephrol 2003. 14:1584-1590.
9. Thadhani RI, Camargo CA, Xavier RJ, Fang LST, Bazari H. Atheroembolic renal failure after invasive procedures: natu-ral history based on 52 histologically proven cases. Medicine 1995. 74: 350-358.
10. Scoble JE. Is nihilism in the treatment of atheroembolic dis-ease at an end? Am J K Dis 1999. 33:975-976.
11. Hasegawa M, Kawashima S, Shikano M, Hasegawa H, Tomita M, Murakami K, Kushimoto H, Katsumata H, Toba T, Oohashi A, Hiramitsu S, Matsunaga K. The evaluation of corticosteroid therapy in conjunction with plasma exchange in the treatment of cholesterol embolic disease. Am J Nephrol 2000. 20:263-267.
12. Cappiello RA, Espinoza LR, Adelman H, Aguillar J, Vasy FB, Germain BF. Cholesterol embolism: a pseudovasculitic syndrome. Semin Arthritis and Rheumatism 1989; 18: 24-26.
13. Boero R, PIgnataro A, Rollino C, Quarello F. Do corticos-teroids improbe survival in acute renal failure due to choles-terol atheroembolism? Nephrol Dial Transplant 2000. 15:441.
14. Espejo SB, Herrero JC, Torres A, Martinez A, Gutierrez E, Morales E, Gonzalers E, Bueno B, Valentin MO, Praga M. Immunoallergic interstitial nephritis vs cholesterol athero-embolism. Differentiating characteristics. Nefrologia 2003. 23:125-130.
15. Takahashi T, Konta T, Nishida W, Igarashi A, Ichikawa K, Kubota I. Renal cholesterol embolic disease effectively treated with steroid pulse therapy. Intern Med 2003. 42:1206-9.